XLV traded relatively flat last week, narrowly underperforming the S&P 500. Overall, the ETF remains constructive,
holding at new highs above all major moving averages with quality growth ideas leading the sector. Megacap bellwethers
(DHR, EW, ISRG, LLY, ZTS) are hitting higher highs and driving the ETF higher.
Over the last month, Bioproduction/tools have handily outperformed the broader market, along with CRO’s, Medical
Devices and Managed Care. Conversely, Biotech, Generic drugs, and Drug distributors have lagged.
